Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: liraglutide

First Posted Date: 2010-08-10

Last Posted Date: 2019-07-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 9341

Registration Number: NCT01179048

Locations: 🇬🇧
Novo Nordisk Investigational Site, West Midlands, United Kingdom

A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec/insulin aspart
Drug: biphasic insulin aspart 30

First Posted Date: 2010-08-03

Last Posted Date: 2017-02-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 28

Registration Number: NCT01174303

Locations: 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria

Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec/insulin aspart
Drug: insulin aspart
Drug: insulin degludec

First Posted Date: 2010-08-02

Last Posted Date: 2013-11-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 27

Registration Number: NCT01173926

Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: insulin aspart
Drug: insulin detemir

First Posted Date: 2010-07-20

Last Posted Date: 2017-02-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 401

Registration Number: NCT01165684

Locations: 🇸🇮
Novo Nordisk Investigational Site, Trbovlje, Slovenia

A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: insulin degludec

First Posted Date: 2010-07-01

Last Posted Date: 2017-01-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 49

Registration Number: NCT01154881

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers

Phase 1

Completed

Conditions: Acquired Bleeding Disorder
Cardiac Surgery Requiring Cardiopulmonary Bypass
Healthy

Interventions: Drug: placebo
Drug: catridecacog

First Posted Date: 2010-06-30

Last Posted Date: 2014-06-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01153997

A Trial Comparing the Effect of NN1250 After Different Routes of Injection in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: insulin degludec

First Posted Date: 2010-06-25

Last Posted Date: 2017-01-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 20

Registration Number: NCT01151072

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A

Phase 3

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: turoctocog alfa

First Posted Date: 2010-06-07

Last Posted Date: 2017-03-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 65

Registration Number: NCT01138501

Locations: 🇹🇷
Novo Nordisk Investigational Site, Izmit, Turkey

A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes

Interventions: Drug: insulin degludec/insulin aspart

First Posted Date: 2010-06-07

Last Posted Date: 2017-02-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 38

Registration Number: NCT01138488

Locations: 🇩🇪
Novo Nordisk Investigational Site, Hannover, Germany

A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes

Interventions: Drug: insulin degludec
Drug: insulin detemir

First Posted Date: 2010-06-03

Last Posted Date: 2017-01-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 22

Registration Number: NCT01135927

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy